An update on the management of systemic lupus erythematosus

Ragan Sweet, Soheyla Mahdavian, Angela Singh, Patty Ghazvini, Ta’Shae McKinnon, Deidra Jones

Abstract


Systemic lupus erythematosus (SLE) is an autoimmune disease that affecting at least 1.5 million Americans. The exact cause of SLE is unknown; however there are numerous factors that are thought to play a role in the development of SLE. While there are several medications available for the management of SLE, Belimumab is the first medication approved for SLE management in over 50 years. Researchers are investigating other medications that may provide some benefit in SLE management and improve patient outcomes. These emerging treatments explore other mechanisms for management and targeting symptoms. SLE has a higher mortality rate than other rheumatic diseases and new and continuous research is needed with the aim to decrease the number of deaths and improve patients’ quality of life.



Full Text: PDF DOI: 10.5430/jhm.v3n2p16

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Journal of Hematological Malignancies
ISSN 1925-4024 (Print)   ISSN 1925-4032 (Online)
Copyright © Sciedu Press  
To make sure that you can receive messages from us, please add the 'Sciedu.ca' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders